Invivyd, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated $13.1 million in product revenue for the third quarter, a 41% increase from $9.3 million in the same period last year. For the nine months ended September 30, 2025, total revenue reached $36.2 million, compared to $11.6 million for the same period in 2024. This growth is attributed to increased sales of PEMGARDA, the company's monoclonal antibody authorized for emergency use against COVID-19.
Despite the revenue increase, Invivyd reported a net loss of $10.5 million for the third quarter, a notable improvement from a loss of $60.7 million in the prior year. For the nine-month period, the net loss was $41.4 million, down from $151.5 million in 2024. The reduction in losses is largely due to a significant decrease in research and development expenses, which fell to $8.0 million in Q3 2025 from $57.9 million in Q3 2024, reflecting a strategic shift in resource allocation as the company focuses on advancing its product pipeline.
Operationally, Invivyd has made strides in its clinical development programs. The company is advancing VYD2311, a next-generation monoclonal antibody candidate for COVID-19, which has shown promising results in early clinical trials. The FDA has cleared the company's Investigational New Drug application for VYD2311, and two pivotal clinical trials, DECLARATION and LIBERTY, are expected to commence by the end of 2025. These trials aim to evaluate the efficacy and safety of VYD2311 in preventing symptomatic COVID-19.
As of September 30, 2025, Invivyd's total assets amounted to $139.2 million, up from $129.5 million at the end of 2024. The company reported cash and cash equivalents of $85.0 million, an increase from $69.3 million at the end of the previous year. However, the company also noted substantial doubt about its ability to continue as a going concern, indicating that it may require additional funding to support ongoing operations and development efforts. The company plans to pursue various funding avenues, including equity offerings and collaborations, to ensure its financial stability moving forward.
Looking ahead, Invivyd remains focused on the commercialization of PEMGARDA and the development of VYD2311, while also exploring potential expansions into other viral diseases. The company’s ability to navigate the complexities of drug development and secure necessary funding will be critical to its future success in the biopharmaceutical landscape.
About Invivyd, Inc.
Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibodies for viral infectious diseases, starting with COVID-19. Its core products include PEMGARDA for COVID-19 pre-exposure prophylaxis and VYD2311, a next-generation antibody candidate. The company leverages antibody discovery, engineering, and surveillance to create long-lasting, broadly neutralizing therapies, partnering with contract manufacturers and research organizations to support development, manufacturing, and commercialization.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.